Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Malignant Neoplasms
|
1641 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.030 | 0.667 | 3 | 2016 | 2019 | ||||||
Breast Carcinoma
|
2793 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.020 | 1.000 | 2 | 2016 | 2017 | ||||||
Malignant neoplasm of breast
|
3417 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.020 | 1.000 | 2 | 2016 | 2017 | ||||||
Primary malignant neoplasm
|
1374 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.020 | 0.500 | 2 | 2018 | 2019 | ||||||
Carcinoma, Ovarian Epithelial
|
327 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Childhood Acute Lymphoblastic Leukemia
|
261 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Colorectal Carcinoma
|
1962 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
Conventional (Clear Cell) Renal Cell Carcinoma
|
222 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Diabetes
|
710 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||||
Diabetes Mellitus
|
824 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||||
Epithelial ovarian cancer
|
129 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Liver carcinoma
|
942 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Lymphoma, Large-Cell, Follicular
|
6 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Lymphoma, Non-Hodgkin
|
197 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Lymphoma, Non-Hodgkin, Familial
|
79 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
Malignant neoplasm of prostate
|
1082 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Non-Small Cell Lung Carcinoma
|
712 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||||
Peripheral T-Cell Lymphoma
|
10 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Prostate carcinoma
|
1168 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Squamous cell carcinoma of esophagus
|
329 | 0.689 | 0.360 | 12 | 123409283 | 3 prime UTR variant | C/G;T | snv | 0.010 | 1.000 | 1 | 2016 | 2016 |